NuVasive (NASDAQ: NUVA) and Ocular Therapeutix (NASDAQ:OCUL) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

Analyst Recommendations

This is a summary of current ratings for NuVasive and Ocular Therapeutix, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NuVasive 1 2 11 0 2.71
Ocular Therapeutix 0 2 4 0 2.67

NuVasive presently has a consensus price target of $79.75, indicating a potential upside of 43.80%. Ocular Therapeutix has a consensus price target of $24.00, indicating a potential upside of 288.35%. Given Ocular Therapeutix’s higher possible upside, analysts clearly believe Ocular Therapeutix is more favorable than NuVasive.

Earnings and Valuation

This table compares NuVasive and Ocular Therapeutix’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
NuVasive $1.02 billion 2.76 $225.78 million $0.62 89.45
Ocular Therapeutix $1.90 million 94.51 -$54.64 million ($2.13) -2.90

NuVasive has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than NuVasive, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares NuVasive and Ocular Therapeutix’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
NuVasive 3.50% 13.04% 5.81%
Ocular Therapeutix -3,005.52% -101.03% -69.76%

Institutional and Insider Ownership

53.4% of Ocular Therapeutix shares are held by institutional investors. 1.2% of NuVasive shares are held by company insiders. Comparatively, 26.1% of Ocular Therapeutix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Risk & Volatility

NuVasive has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Comparatively, Ocular Therapeutix has a beta of 1.6, meaning that its stock price is 60% more volatile than the S&P 500.

Summary

NuVasive beats Ocular Therapeutix on 8 of the 13 factors compared between the two stocks.

About NuVasive

Nuvasive, Inc. is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process. Its principal product offering includes a minimally-disruptive surgical platform called Maximum Access Surgery (MAS). The platform includes its software-driven nerve detection and avoidance systems, including NVM5, and intraoperative monitoring services and support; MaXcess, an integrated split-blade retractor system, and a range of implants and biologics. The platform combines three product categories: its MaXcess retractors, specialized implants and fixation products, and nerve monitoring systems and service offerings that collectively enable surgeons to detect and navigate around nerves, while directing customized access to the spine for implant delivery.

About Ocular Therapeutix

Ocular Therapeutix, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye. Its lead product candidates are DEXTENZA (dexamethasone insert), for the treatment of post-surgical ocular inflammation and pain, allergic conjunctivitis and dry eye disease, and OTX-TP, for the treatment of glaucoma and ocular hypertension, which are extended-delivery, drug-eluting inserts that are placed into the canaliculus through a natural opening called the punctum located in the inner portion of the eyelid near the nose. It also has an intravitreal hydrogel depot, which is in preclinical development for the treatment of diseases and conditions of the back of the eye, including wet age-related macular degeneration (wet AMD).

Receive News & Ratings for NuVasive Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.